MPLT - MapLight Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$29.20
DETAILS
HIGH:
$46.00
LOW:
$13.00
MEDIAN:
$28.00
CONSENSUS:
$29.20
UPSIDE:
124.62%
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0.6 | 0.7 | 0.6 | 0.6 |
| Gross Profit | (0.6) | (0.7) | (0.6) | (0.6) |
| Operating Expenses | ||||
| R&D Expenses | 137.8 | 67.8 | 49.1 | 26.6 |
| SG&A Expenses | 30.7 | 14.4 | 7.6 | 4.1 |
| Other Expenses | 0 | 0 | 0 | 0 |
| Operating Expenses | 168.5 | 82.2 | 56.7 | 30.7 |
| Operating Income | ||||
| Operating Income | (169.1) | (82.9) | (57.3) | (31.2) |
| Interest Expense | 0 | 0 | 0 | 0 |
| Interest Income | 5.5 | 4.5 | 1.1 | 0.4 |
| Profitability | ||||
| EBITDA | (160.6) | (76.9) | (55.2) | (29.4) |
| EBIT | (161.2) | (77.6) | (55.7) | (30.0) |
| Income Before Tax | (161.2) | (77.6) | (55.7) | (30.0) |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (161.2) | (77.6) | (55.7) | (30.0) |
| Per Share Data | ||||
| EPS (Basic) | -3.66 | -1.87 | -1.34 | -0.72 |
| EPS (Diluted) | -3.66 | -1.87 | -1.34 | -0.72 |
| Shares Outstanding | 44.0 | 41.4 | 41.4 | 41.4 |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Current Assets | ||||
| Cash & Cash Equivalents | 46.7 | 38.3 | 79.8 | 27.7 |
| Short-Term Investments | 258.4 | 70.5 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Other Current Assets | 19.6 | 0 | 3.8 | 4.4 |
| Total Current Assets | 324.7 | 114.6 | 83.6 | 32.0 |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 6.6 | 7.6 | 6.6 | 7.1 |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 148.2 | 11.6 | 1.2 | 0.2 |
| Other Non-Current Assets | 0.1 | 3.2 | 0 | 0 |
| Total Non-Current Assets | 154.8 | 22.3 | 7.8 | 7.4 |
| Total Assets | 479.5 | 136.9 | 91.4 | 39.4 |
| Current Liabilities | ||||
| Account Payables | 0 | 1.9 | 0 | 0 |
| Short-Term Debt | 0.9 | 0.8 | 0.5 | 0.3 |
| Deferred Revenue | 0 | 3.2 | 4.2 | 5.9 |
| Other Current Liabilities | 9.2 | 6.0 | 7.2 | 4.9 |
| Total Current Liabilities | 16.2 | 15.9 | 14.7 | 12.6 |
| Non-Current Liabilities | ||||
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Total Non-Current Liabilities | 4.9 | 5.8 | 5.4 | 5.9 |
| Total Liabilities | 21.1 | 21.7 | 20.1 | 18.5 |
| Stockholders' Equity | ||||
| Common Stock | 0.0 | 0 | 0 | 0 |
| Retained Earnings | (360.5) | (199.4) | (121.8) | (66.1) |
| Accumulated Other Comprehensive Income | (0.2) | 0.2 | 0 | 0 |
| Total Stockholders' Equity | 458.4 | 115.2 | 71.3 | 20.9 |
| Total Liabilities & Equity | 479.5 | 136.9 | 91.4 | 39.4 |
| Debt Metrics | ||||
| Total Debt | 5.8 | 6.6 | 5.9 | 6.3 |
| Net Debt | (40.9) | (31.7) | (73.8) | (21.4) |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | (161.2) | (77.6) | (55.7) | (30.0) |
| Depreciation & Amortization | 0.6 | 0.7 | 0.6 | 0.6 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Change in Working Capital | (12.8) | (3.1) | 2.0 | 1.7 |
| Other Non-Cash Items | 35.3 | 1.1 | 1.1 | 1.1 |
| Operating Cash Flow | (138.1) | (78.8) | (52.0) | (26.6) |
| Investing Activities | ||||
| Capital Expenditure | (0.5) | (0.8) | (0.5) | (0.7) |
| Acquisitions | 0 | 0 | 0 | 0 |
| Purchases of Investments | (408.2) | (125.0) | 0 | 0 |
| Sales/Maturities of Investments | 85.5 | 45 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (323.2) | (80.8) | (0.5) | (0.7) |
| Financing Activities | ||||
| Net Debt Issuance | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.0) | (2.2) | 0 | 0 |
| Financing Cash Flow | 469.8 | 118.1 | 104.6 | 33.2 |
| Cash Position | ||||
| Net Change in Cash | 8.5 | (41.5) | 52.1 | 27.7 |
| Cash at Beginning | 38.3 | 79.8 | 27.7 | 0 |
| Cash at End | 46.7 | 38.3 | 79.8 | 27.7 |
| Free Cash Flow | (138.6) | (79.6) | (52.5) | (27.3) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | (0.6) | (0.7) | (0.6) | (0.6) |
| Operating Income | (169.1) | (82.9) | (57.3) | (31.2) |
| Net Income | (161.2) | (77.6) | (55.7) | (30.0) |
| EPS (Diluted) | -3.66 | -1.87 | -1.34 | -0.72 |
| Balance Sheet | ||||
| Cash & Equivalents | 46.7 | 38.3 | 79.8 | 27.7 |
| Total Assets | 479.5 | 136.9 | 91.4 | 39.4 |
| Total Debt | 5.8 | 6.6 | 5.9 | 6.3 |
| Stockholders' Equity | 458.4 | 115.2 | 71.3 | 20.9 |
| Cash Flow | ||||
| Operating Cash Flow | (138.1) | (78.8) | (52.0) | (26.6) |
| Capital Expenditure | (0.5) | (0.8) | (0.5) | (0.7) |
| Free Cash Flow | (138.6) | (79.6) | (52.5) | (27.3) |